0001104659-22-096653 4 1 20220829 20220831 20220831 Hagopian Henry III 0001821822 4 34 001-39202 221219276 C/O ORGANOGENESIS INC., 85 DAN ROAD CANTON MA 02021 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 4 1 tm2224852-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-08-29 0 0001477845 Annovis Bio, Inc. ANVS 0001821822 Hagopian Henry III C/O ANNOVIS BIO, INC. 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 0 1 0 0 Chief Financial Officer Stock Option (right to buy) 11.55 2022-08-29 4 A 0 120000 0 A 2032-08-29 Common Stock 120000 120000 D The stock option vests one-third on August 29, 2023 and the remaining two-thirds will vest in eight consecutive quarterly installments beginning the fifteenth month after August 29, 2022, and will vest in full upon a Change of Control (as defined in the Company's 2019 Equity Incentive Plan), with vesting conditioned on continued employment on the applicable vesting dates. /s/ Henry Hagopian, III 2022-08-31